Goldman Sachs Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $76
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a Buy rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and raises the price target from $67 to $76.
August 02, 2024 | 4:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs analyst Salveen Richter maintains a Buy rating on Ultragenyx Pharmaceutical and raises the price target from $67 to $76.
The Buy rating and increased price target from a reputable analyst at Goldman Sachs is likely to positively impact investor sentiment and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100